Participating Organizations

Rick Williams, Ph.D.

Dr. Rick Williams is a fellow of the American Statistical Association (ASA) with more than 30 years of experience in medical and epidemiological research. He has led eight major multisite research projects coordinating the efforts of dozens of research sites across the US. He designs and leads population surveys, observational studies, and randomized clinical trials. He frequently conducts workshops and training classes on the use of statistical analysis methods for cluster-correlated, longitudinal, or repeated measures data, such as generalized estimating equations for marginal models, hierarchical linear and nonlinear mixed models, and multilevel models. He has also led the selection and implementation of data capture and data management systems for clinical studies at RTI International. He holds a Ph.D. in Biostatistics with specialization in Epidemiology. Dr. Williams is the PASA Data Coordinating Center Principal Investigator.

www.rti.org

Tracy Nolen, DrPH

Dr. Tracy Nolen is a senior research statistician with more than 13 years of experience providing and managing analytic support for observational studies and clinical trials funded by commercial pharmaceutical and device companies, the Department of Defense (DoD), Department of Veteran Affairs (VA), and the National Institutes of Health (NIH). Dr. Nolen holds a Doctor of Public Health degree in Biostatistics from the University of North Carolina at Chapel Hill’s Gillings School of Global Public Health and a master’s degree in Statistics from North Carolina State University. She specializes in the design, set-up, operation, analysis as well as scientific and regulatory reporting of clinical trials. Her statistical experience includes causal inference in observational and randomized trials settings; alternative study designs including adaptive dose finding designs and adaptive randomization algorithms; and the use of various statistical methods (e.g., regression analysis, including generalized linear models; longitudinal data analysis, including generalized estimating equation (GEE) and mixed models; survival analysis; nonparametric analysis; dose-proportionality analysis). Dr. Nolen holds a Doctorate of Public Health in biostatistics from the University of North Carolina at Chapel Hill’s Gillings School of Global Public Health and a master’s degree in statistics from North Carolina State University. She is a PASA Data Coordinating Center Co-Principal Investigator.

www.rti.org

Meg Crawford

Meg M. Crawford is a research clinical studies specialist and manager in the Center for Clinical Research Network Coordination at RTI International. She has more than 13 years of experience managing clinical trials in multi-site networks, is certified as a clinical research professional, and is trained in good clinical practices. Ms. Crawford serves as the clinical research manager on the Pharmacotherapies for Alcohol and Substance Abuse Consortium (PASA). Her responsibilities include developing protocols, study manuals, and informed consent documents; developing or monitoring case report forms; reviewing adverse event experience reports; and ensuring protection of subjects and subjects’ rights through institutional review board relations. Ms. Crawford’s responsibilities also include budget development, report preparation, education and protocol training of other research professionals, project administration, and research project audits.

www.rti.org

Nathan Vandergrift

Nathan Vandergrift is a statistician with more than 15 years of experience in collaborative research in diverse areas from large-scale educational and child development to public health–related infectious disease, translational medicine from bench, and vaccine and treatment. His areas of statistical expertise are structural equation modeling, nonlinear and linear mixed-effects modeling, generalized linear models, nonparametric statistics, missing data, and statistical matching. Dr. Vandergrift has a depth of experience applying for, receiving, and executing large multisite UM1 and P01 grants and contracts and R01-level grants. He has led statistical teams and been a part of large collaborative research groups spanning many sites, countries, and continents. These collaborations have resulted in publications in highly regarded peer-reviewed journals. Dr. Vandergrift serves as a Senior Statistician for the PASA Study Data Coordinating Center.

www.rti.org

Keith LeGrow

Keith LeGrow has 18 years of experience in business analysis, application systems management and business software development, including use of Agile methodologies. He has extensive experience organizing and managing complex software projects in pharmaceutical and agricultural R&D. He has a diverse array of technical skills, enriched by extensive professional and in-house training and extensive experience working in cross-functional, multinational teams. Mr. LeGrow is the Systems Analyst for the PASA Study Data Coordinating Center.

www.rti.org

Lauren Bradley, MHS

Lauren Bradley is a research public health analyst at RTI International. She has extensive experience working in public health, with experience in medical school curriculum design and management, public health research, global education research, and environmental health research and program management. Ms. Bradley’s particular public health interests include public health laboratories and preparedness, field epidemiology training and education, medical curriculum development and implementation, and environmental health. In her current role at RTI international, she provides research support and project management expertise for clinical trials and drug development projects for a variety of conditions and research topics in the fields of epidemiology and public health.

www.rti.org

Amy Kendrick

Amy Stirling Kendrick is a project manager and study manager within the Center for Clinical Research Network Coordination (CRNC). She serves as the overall project manager for the Chronic Effects of Neurotrauma Consortium (CENC). As a study manager she runs several CENC projects and is a team member on the RTI initiative to centralize and standardize safety reporting procedures across coordinating centers. She is also a Study Manager for the PASA Study Data Coordinating Center. Ms. Kendrick has 14 years of patient care experience and more than 16 years of clinical research experience. Her patient care experience, primarily in pediatrics, ranged from outpatient to inpatient and then to Intensive Care Unit (ICU) settings. Her research experience has spanned from hospital site coordinator, to Clinical Research Office (CRO) coordinator and pharmacovigilance specialist.

www.rti.org

Ben Carper, MS

Benjamin Carper is a research statistician at RTI International. He has more than 7 years of experience in analyzing data, writing reports, and leading tasks from a variety of different scientific and financial disciplines, including preclinical studies and clinical trials, terrorism risk assessment, travel surveys, financial credit risk modeling, and infectious disease outbreak modeling. Additional scientific disciplines include adverse health outcome prediction, environmental pollutant impact studies, biological and chemical agent exposure and treatment efficacy modeling, and genetic clustering. Mr. Carper has experience with using many statistical methods, including survival analysis, multivariate regression, nonlinear and mixed models, machine learning, classification algorithms, text analysis, risk assessment, meta-analysis, pattern recognition, and power analysis. He also has extensive experience in data simulation and analysis and in combining data from multiple sources.

www.rti.org

Greg Gatto

Gregory Gatto is a senior research pharmacologist in RTI International’s Center for Global Health. He has more than 15 years of drug development experience and has directed scientific research programs from target validation (TV) to first-time-in-human (FTIH) in therapeutic areas including psychiatry, neurology, respiratory, metabolic and gastrointestinal diseases. Dr. Gatto managed research strategies that repurposed unwanted clinical endpoints into new clinical indications. He has established an excellent track record in submitting dossiers to regulatory agencies and has extensive expertise in nonclinical safety assessment. Before joining RTI, Dr. Gatto held the following positions: senior director of behavioral pharmacology at Melior Discovery, CEO/co-founder of Biolucidation LLC, cofounder of AlphaSyx Therapeutics, senior director of preclinical pharmacology at Targacept, and an independent research contractor for Aventis Pharma. Dr. Gatto did his postdoctoral fellowship at Wake Forest University, focusing on profiling drug-attenuating agents in animal models of addiction. His graduate studies at Indiana University were focused on mapping drug reinforcing sites in brain regions of rodents using an innovative drug delivery device and preclinical evaluation of potential pharmacotherapies in the treatment of alcoholism. Dr. Gatto has produced more than 100 publications, patents, and presentations. He is the Safety Lead for the PASA Study Data Coordinating Center.

www.rti.org

Callie Riggs, MBA

Callie Riggs joined RTI International in 2006 as a financial analyst. She has since transitioned to the role of project administration specialist. In this role, Ms. Riggs has managed the contractual, administrative, and fiscal affairs for an international multisite research project, several small international projects, and several national multisite projects. Ms. Riggs assisted with the development of the capitation payment system for a large research project, and she is knowledgeable about making capitation payments in a multisite, multiple protocol project. - She has previous experience developing proposal budgets for a variety of contract types at RTI International. Ms. Riggs also has experience with program administration, cost accounting, contract management, and financial reporting.

www.rti.org

Gene Turner

Gene Turner is a senior clinical data manager at RTI International. He has 22 years of experience in the pharmaceutical industry and has comprehensive knowledge of the clinical drug development process for project-lead clinical data management. As a senior clinical data manager at RTI International, Mr. Turner ensures database accuracy according to departmental operating procedures, performs a quality control review of the data and coordinates corrections to the database with the clinical sites, and designs case report forms (CRFs) for data acquisition and data entry. Mr. Turner also oversees development of electronic case report forms (eCRFs), develops data management plans, and monitors study metrics.

www.rti.org

Meghan Calabro

Meghan C. Calabro is currently a Clinical Study Specialist in the Clinical Research Network Center at RTI International. In this capacity, she works collaboratively to provide comprehensive technical and administrative support to health research project teams. She also supports data management efforts, proposal writing, regulatory tracking, and quality management procedures, and assists with managing correspondence and project communications. Ms. Calabro’s interests stretch broadly from clinical research to epidemiological studies. She consistently works to broaden her background in public health and is eager to jump on any new opportunity that allows her to increase her project and data management skills and knowledge of current health issues that impact the world globally. Ms. Calabro is a Research Assistant for the PASA Study Data Coordinating Center.

www.rti.org

Shawn Hirsch

Shawn Hirsch is a research statistician in the Biostatistics and Epidemiology Unit at RTI International. In this capacity, he works with a multidisciplinary team to design, implement, manage, and analyze observational studies and multisite randomized clinical trials. His specific job duties include, but are not limited to, the following: developing data safety reports, creating edit checks and other data quality reports, performing data manipulations and statistical analyses, and collaborating with investigators to prepare abstracts and manuscripts. Mr. Hirsch has a diverse portfolio of experience in a variety of research topics, including traumatic brain injury, post-traumatic stress disorder (PTSD), cancer, HIV/AIDS, and environmental health expertise. His statistical skills include sensitivity and specificity calculations; categorical data analysis; linear, logistic, and Poisson regressions; generalized linear models; and survival analysis. He has 6 years of experience with SAS, including arrays, macros, reporting, statistical programming, and rtf output. He also has 4 years of background in government contracting, including 2 years of project management experience. Mr. Hirsch is a Study Statistician for the PASA Study Data Coordinating Center.

www.rti.org

Kayla Nowak

Kayla Nowak is a statistician who joined RTI International in December 2015. She is currently contributing to the analysis and imputation teams for the National Survey of Drug Use and Health (NSDUH), the analysis team for Analytic Support Center (ASC), the biostatistics and data management core for the Chronic Effects of Neurotrauma Consortium (CENC), the biostatistics core for the Pharmacotherapies for Alcohol and Substance Abuse Consortium (PASA), the statistical review team for the Synar Survey Assessment, and the evaluation core for Rockefeller Yieldwise Waste and Spoilage Initiative. Ms. Nowak is a Study Statistician for the PASA Study Data Coordinating Center. She came to RTI after graduating from Penn State University with a bachelor’s degree in statistics and biostatistics focus. While at Penn State, Ms. Nowak was a research assistant in a plant ecology lab that studied potential risks of using virus-resistant transgenes in an agricultural setting.

www.rti.org

Ryan Whitworth

Ryan Whitworth, currently a statistician in RTI International’s Biostatistics and Epidemiology Division, has more than 14 years of research experience and skills in data processing, data management, statistical programming, and analysis. Before joining RTI, he used these skills in clinical data management of oncology trials in the National Cancer Institute’s (NCI’s) Cancer Trials Support Unit. Mr. Whitworth’s experience in academia included management and analysis of data from epidemiologic studies of adolescent health, childhood cancers, and occupational hazards of migrant farm workers and their children. Currently, he provides statistical support through clinical data management, quality control, and statistical programming. Mr. Whitworth is a Study Statistician for the PASA Study Data Coordinating Center.

www.rti.org

Thomas Kosten, M.D.

Dr. Kosten is a professor and the Jay H. Waggoner Endowed Chair in the Menninger Department of Psychiatry and Behavioral Sciences at Baylor College of Medicine (BCM), as well as the co-director of the Dan L. Duncan Institute for Clinical and Translational Research (ICTR) at BCM. He has led National Institutes of Health (NIH) and VA Research Centers and randomized clinical trials for over 30 years and has been PI on several national multisite studies for developing new medications in many addictions and post-traumatic stress disorder (PTSD). He has directed a National Institute on Drug Abuse (NIDA) Medications Development Center since 1988 and has been the Research Director of the VA National Substance Use Disorders Quality Enhancement Research Initiative (QUERI) based at the Michael E. DeBakey VA Medical Center (MEDVAMC). He is the founding Vice Chair for Addiction Psychiatry of the American Board of Psychiatry and Neurology, and Past President of both the American Academy of Addiction Psychiatry (AAAP) and the College on Problems of Drug Dependence (CPDD). He is a Distinguished Life Fellow in the American Psychiatric Association (APA) and a Fellow of the American College of Neuropsychopharmacology (ACNP). He has served as a Congressional Fellow in the US House of Representatives and has been a long-standing member of various substance abuse commissions for the National Academy of Sciences (NAS), as well as various advisory boards for the Food and Drug Administration (FDA) and the Department of Defense (DoD). He is the current editor for the American Journal on Addictions, past Editor for the American Journal of Drug and Alcohol Abuse and serves on the board of several notable journals in substance abuse. He has published over 700 papers, books, and reviews describing his contributions, particularly in the use of pharmacotherapeutics for treating cocaine and opioid addictive disorders, as well as his work in vaccine development for cocaine and methamphetamine addictions. Dr. Kosten is the Co-PI for the PASA Consortium. He is also the Co-PI for the PASA funded study entitled “PT150 as a Potential Treatment for Alcohol Use Disorder- Alcohol Interaction Study”, as well as the Co-PI for the “Zonisamide as a New Treatment for Post-Traumatic Stress Disorder and Co-Occurring Alcohol Use Disorder Study”.

www.bcm.edu

Christopher Verrico, Ph.D.

Dr. Christopher Verrico is an assistant professor in the Department of Pharmacology at Baylor College of Medicine (BCM) with nearly 20 years of training and experience conducting research in the area of substance use disorders (SUD). His past research has focused on discovering and evaluating treatments for narcotic and alcohol addictions. He has experience in both animal and clinical research on different forms of addiction. He has led clinical research projects with Veterans at the Michael E. DeBakey VA Medical Center (MEDVAMC) and the National Institutes of Health (NIH), including the National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA). He currently directs two NIH-funded clinical studies that are being conducted at the MEDVAMC. For the past year, he has lead Dr. Newton’s NIDA-funded study (R01 DA 035513) evaluating the efficacy of treatment with both modafinil and doxazosin for reducing cocaine-induced effects. He also directs Dr. Newton’s NIAAA-funded study (R42 AA 22049) exploring the efficacy of carisbamate for treating alcohol use disorder (AUD) in civilians. Dr. Verrico is the PI of the following PASA-funded clinical trials, “PT150 (formerly ORG 34517) as a Potential Treatment for Alcohol Dependence – “Alcohol Interaction Study”, “Zonisamide as a New Treatment for PTSD & Co-Occurring AUD”, and “Effects of Ethanol on the Pharmacokinetics of PT-150.”

www.bcm.edu

Howard C. Becker, Ph.D.

Dr. Howard C. Becker is a professor in the Departments of Psychiatry and Neuroscience at the Medical University of South Carolina (MUSC) and a Senior Research Career Scientist at the Ralph H. Johnson VA Medical Center. Dr. Becker has over 30 years of research experience in the use of animal models to determine the basic mechanisms of alcohol and drug action in the brain. Additionally, as Director of the Charleston Alcohol Research Center, Dr. Becker coordinates preclinical and clinical investigations that focus on identifying and evaluating alcohol treatment targets and strategies. He also serves as the Scientific Director for the NIAAA-supported Integrative Neurobiology Initiative on Alcoholism (INIA-Stress) Consortium, a multi-institutional consortium focused on understanding the neuroadaptive changes that result from the complex interaction between stress, anxiety, and alcohol use/misuse in several species (rodents, monkeys, and humans). He is the PI of the PASA-funded preclinical study entitled “Preclinical Analysis of Combined Zonisamide and Doxazosin Treatments in Stress-Alcohol Drinking Models”.

http://academicdepartments.musc.edu/musc/

Marcelo Lopez, Ph.D.

Dr. Marcelo Lopez is an associate professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina (MUSC), a Principle Investigator of the INIA-Stress Consortium Mouse CIE Core, and the Animal Core Supervisor of the Shared Resources Core within the Charleston Alcohol Research Center. Dr. Lopez has extensive experience in conducting behavioral pharmacology studies that utilize numerous rodent models of alcohol exposure, including a chronic intermittent ethanol (CIE) exposure model that produces escalation of drinking. Dr. Lopez was instrumental in the development of the CIE model, which is now widely employed in the alcohol research field. He has also studied the complex interaction of stress and alcohol, work which led to the development of several stress/PTSD models. He is the Co-Investigator of the PASA-funded preclinical study entitled “Preclinical Analysis of Combined Zonisamide and Doxazosin Treatments in Stress-Alcohol Drinking Models”.

http://academicdepartments.musc.edu/musc/

Colin N. Haile, M.D., Ph.D.

Dr. Colin N. Haile is a research assistant professor in the Department of Psychology and Operations Director of the Animal Behavioral Core (ABC), a core facility designed to conduct experimental procedures in rats and mice, at the University of Houston. Dr. Haile has nearly 20 years of experience in evaluating potential pharmacotherapies for psychiatric diseases in humans and in animal models. He has a broad range of experience in molecular, behavioral, and clinical experimental procedures, and has published extensively on using a variety of behavioral assays for medication development. Dr. Haile also has a joint appointment at the Michael E. DeBakey VA Medical Center (MEDVAMC), where he is involved in clinical trials assessing medications for anxiety and substance use disorders (SUD) in Veterans. He is the PI of the PASA-funded preclinical study entitled “Assessing Pharmacotherapies in Animal Models of PTSD and AUD”.

http://www.uh.edu/

Therese Kosten, Ph.D.

Therese A Kosten PhD is Professor of Psychology at the University of Houston. The overarching theme of her research program is to understand the contributions of genetic and environmental factors that influence and shape behavior via the involvement of the hypothalamic-pituitary-adrenal (HPA) axis and dopaminergic and noradrenergic systems. She studies how behaviors reflective of addiction (e.g., self-administration, conditioned place preference, etc) are affected by stress, sex, and early life manipulations. Another aspect of her research can be considered translational as it involves medication development. For example, her laboratory is constructing and testing vaccines for methamphetamine abuse, and they are identifying new pharmacological targets for alcoholism that they test using maintenance and reinstatement of operant responding for alcohol procedures. Broadly, her research program encompasses the areas of motivation, emotion, and learning with a focus on limbic regions, such as the nucleus accumbens and hippocampus. Dr. Kosten is the Co-PI for the PASA study entitled “Assessing Pharmacotherapies in Animal Models of Post- Traumatic Stress Disorder and Alcohol Use Disorder”.

http://www.uh.edu/

Lori Davis, M.D.

Lori Davis, MD, is Associate Chief of Staff for Research at the Tuscaloosa VA Medical Center and Professor of Psychiatry in the Department of Psychiatry, University of Alabama Health System, in Birmingham and Tuscaloosa, AL. She received her undergraduate degree from Duke University and her medical degree from the University of North Carolina at Chapel Hill. She completed psychiatry residency at the University of Alabama at Birmingham. Dr. Davis has been conducting clinical trials in the treatment of posttraumatic stress disorder, major depression, and addictions for over 25 years. She was a member of the American Psychiatric Association Mood Disorders Workgroup on DSM-5 and is a member of the 2017 VA-DoD workgroup for the revision of the Clinical Practice Guidelines for PTSD. She is Study Chair for the VA Cooperative Study Program multisite trial evaluating the efficacy of Individual Placement and Support supported employment in the rehabilitation of unemployed Veterans with PTSD. Dr. Davis is the PI for the PASA funded clinical trial, “Kappa Opioid Receptor Antagonism for the Treatment of Alcohol Use Disorder and Comorbid PTSD.” This study focuses on kappa-opioid receptor antagonism in the treatment of veterans and service members recovering from alcohol use disorders (AUD) and comorbid posttraumatic stress disorder (PTSD). The multi-site study evaluates the efficacy and physiological effects of sublingual buprenorphine (Subutex) combined with extended-release injectable naltrexone (Vivitrol) in the treatment of comorbid AUD and PTSD. Sublingual buprenorphine, which acts as an antagonist at kappa and partial agonist of the mu receptors, combined with extended-release injectable naltrexone, which blocks the mu receptor, yields a pharmacologically net effect of kappa opioid receptor (KOR) antagonism.

https://www.tuscaloosa.va.gov/TUSCALOOSA/services/research/TREAC.asp

Ismene Petrakis, M.D.

Dr. Ismene Petrakis is Professor of Psychiatry at the Yale University School of Medicine and the Chief of Psychiatry and Mental Health Services at VA Connecticut Healthcare System. She is also the Director of the Addiction Psychiatry Residency at Yale University School of Medicine and the principal investigator of a National Institute of Drug Abuse (NIDA-T32) training grant. She is involved in the education of medical students and residents at many stages of their training, particularly around clinical issues of addictive disorders. She is also a grant funded investigator (funding sources over the years have included NIH, VA, Department of Defense, NARSAD and the Stanley Foundation) whose research interests include developing an understanding of the neurobiology of alcohol dependence and in testing potentially effective treatments for individuals with alcohol dependence and comorbid Axis I psychiatric disorders, particularly PTSD. Dr. Petrakis is the Co-PI for the PASA trial, “Kappa Opioid Receptor Antagonism for the Treatment of Alcohol Use Disorder and Comorbid PTSD.” Dr. Petrakis received her undergraduate degree at Northwestern University and her medical training at the University of Pittsburgh, School of Medicine. She completed her residency training at Yale University School of Medicine and then completed an Addiction Psychiatry Fellowship, also at Yale University. Since completing her training, Dr. Petrakis has over 20 years of experience in the clinical treatment of addictive disorders, research in this field and in the education of residents, medical students, post-doctoral fellows and other mental health trainees in the assessment, accurate diagnosis and treatment of patients with addictive disorders, particularly in those with comorbidity.

Dewleen Baker, M.D.

Dr. Dewleen Baker is a professor in the Department of Psychiatry at the University of California, San Diego (UCSD), Director of Neuroscience/Research at the San Diego Center of Excellence (CESAMH), Director of the Research and Neuroscience Unit, and a teaching attending in the Anxiety Disorders Unit of the San Diego VA Health System (VASDHS). Her research focuses on various aspects of stress and mental health, particularly post-traumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI). Within this focus, her clinical and research activities include projects in neuroscience and neurobiology), treatment of PTSD and mTBI and co-occurring mental and physical disorders (e.g. metabolic and immune-related disorders). She is the PI of the PASA-funded clinical trial entitled “Efficacy and Safety Study of PT150 (formally ORG 34517) in Veterans with Co-morbid PTSD/AUD” and co-PI of the PASA-funded clinical trial entitled “PT150 (formerly ORG 34517) as a Potential Treatment for Alcohol Dependence – Alcohol Interaction Study”.

http://ucsd.edu/

Victoria Risbrough, Ph.D.

Dr. Victoria Risbrough is an associate professor in the Department of Psychiatry at the University of California, San Diego (UCSD), Associate Director of Neuroscience/Research at the San Diego Center of Excellence (CESAMH), a member of the Molecular Neuropharmacology and Signaling study section for National Institutes of Health (NIH), and Director of the Neurocognition Project for the Marine Resiliency Study funded by the US Navy Bureau of Medicine and Surgery (BUMED). Dr. Risbrough’s research is centered on translational mechanisms and treatments of anxiety disorders using preclinical and clinical approaches. Her primary focus is to identify mechanisms of risk and resilience to anxiety disorders, particularly post-traumatic stress disorder (PTSD), as well as development of new pharmacological treatments for these disorders. Her program also identifies genetic and environmental contributions to stress behavior and fear learning. By measuring physiological responses to stress (including heart rate and startle reactivity) in animal models and in clinic, her research develops translational probes of anxiety responding and treatment efficacy. She is the co-PI of the PASA-funded clinical trial entitled “Efficacy and Safety Study of PT150 (formally ORG 34517) in Veterans with Co-morbid PTSD/AUD”.

http://ucsd.edu/

Astellas Pharma

Assessing Pharmacotherapies in Animal Models of Post-Traumatic Stress Disorder and Alcohol Use Disorder (AS140026-A2) – Dr. Colin N. Halie

POP TEST™

Efficacy and Safety Study of PT150 (formerly ORG 34517) in Veterans with Co-morbid PTSD/AUD (AS140026-A3a), PT150 (Formerly ORG34517) as a Potential Treatment for Alcohol Use Disorder – Alcohol Interaction Study (AS140026-A3b), and Effects of Ethanol on the Pharmacokinetics of PT-150 (AS140026-A3c). – Dr. Christopher Verrico and Dr. Dewleen Baker

Alkermes

Kappa Opioid Receptor Antagonism for the Treatment of Alcohol Use Disorder and Comorbid PTSD – Dr. Lori Davis and Dr. Ismene Petrakis

TONIX Pharmaceuticals

Kappa Opioid Receptor Antagonism for the Treatment of Alcohol Use Disorder and Comorbid PTSD – Dr. Lori Davis and Dr. Ismene Petrakis